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NEW STRATEGIES FOR TREATING PAIN IN PATIENTS WITH
OSTEOARTHRITIS
R.L. Leff
AstraZeneca, Wilmington, DE
Purpose:Over the years, a number of means to reduce the pain of
osteoarthritis have been shown to be useful, such as weight loss,
devices, intra-articular injections, and topical and oral medications.
Many are biomechanical in nature, while others are more physio-
logically based; often the result of building upon prior art by using
natural products, including (among many) aspirin, other NSAIDs,
topical capsaicin, intra-articular hyaluronic acids, cannabinoids,
and opioids. Nutritional supplements are often used, albeit with
less convincing evidence. The aim of most treatments is to reduce
pain, permitting greater mobility and ideally less of a need for more
risky or invasive interventions, such as arthroplasty. Some agents
for other diseases acting upon the central nervous system, includ-
ing the spinal cord, have been the source of exploratory studies
in osteoarthritis pain; central nervous system and other adverse
effects however often limit their usage. Agents more focused upon
the peripheral nervous system, such as the dorsal root ganglia,
may have fewer such issues. The challenge in osteoarthritis, with
heterogeneous sources of pain, is to ﬁnd effective interventions
and then also be able to choose those patients with the greatest
likelihood to beneﬁt, as there will usually be some risks involved,
especially with newly approved agents.
Methods: Emerging targets, including anti-NGF monoclonal an-
tibodies, ion channel antagonists (sodium and calcium), ther-
mosensitive ion channels (TRP/VR/vanilloid receptors), selective
cannabinoids, and others, will be discussed from available public
sources.
Results: The current pipeline of published compounds in devel-
opment for the treatment of pain, focusing upon that of possible
relevance to osteoarthritis will be presented.
Conclusions: Future treatment of osteoarthritis will be different
from that today. The search for better and/or additive agents
will continue; however, these will come at a price in known and
unknown safety concerns.
I-15
UPDATE ON MATRIX DEGRADATION: ROLE OF MATRIX
DEGRADATION IN OA
C. Little
Univ. of Sydney, St Leonards, Australia
The key clinical feature of OA is disability associated with joint
pain and varying degrees of swelling, deformity, and decreased
range of motion. OA-disability is predominantly driven by pain,
although other factors such as reduced range of motion, weakness
and/or instability, and psychological phenomena undoubtedly play
a role in the disease burden. Progressive degradation and loss of
articular cartilage is a central although not pathognomonic feature
of OA, and the poor reparative capacity of this tissue means that
its loss may be irreparable. However, OA is a disease of the entire
“joint organ” with pathological change in intra-articular ligaments
and menisci, synovial ﬂuid, synovium, joint capsule and bone,
as well the cartilage. As OA involves pathology in all these joint
tissues, is speciﬁcally targeting cartilage matrix degradation a valid
approach to treating the clinical disease in patients? The answer
depends on which of the pathological tissues contributes most to
the disease pain and disability, and whether inhibiting pathological
change in one tissue, namely cartilage, modulates the others. Pain
in OA does not arise directly from damage to the aneural cartilage.
Sensory neurons are found in the synovium/joint capsule, intra-
articular ligaments and subchondral bone (SCB), with changes in
the latter strongly implicated in recent studies of pain and disease
progression in human knee OA.
Signiﬁcant advances in our understanding of the mechanisms of
cartilage matrix degradation in OA have been made in that past
decade by studying induced or age-related OA in genetically-
modiﬁed or transgenic mice. The effect on OA has been described
in the literature in mice with over 60 different genetic modiﬁcations.
Most of these (40) have reported increased spontaneous OA-like
cartilage damage in mutant mice compared with age-matched
wild-type (WT) animals. In the remaining studies, the response
to induced OA (usually surgical destabilization of the knee) has
been evaluated, with no or mixed effect reported in 10, increased
disease in 6, and signiﬁcant reduction of cartilage matrix damage
in 7 mice. This differential effect of various genetic modiﬁcations
in surgically-induced OA in mice, offers a great opportunity to
investigate the relationship between cartilage matrix degradation
and global joint pathological change. To date however, only 5 of
the published studies have reported on joint tissues other than
cartilage, 3 describing effects on osteophyte development, and in
only 2 the effect of the mutation on OA-induced changes in SCB.
Using histopathology scoring systems we have examined the rela-
tionship between the severity and progression of cartilage matrix
degradation and changes in SCB density, osteophyte maturity
and osteophyte size, over time in surgically-induced OA in 3
different WT mouse strains. The effect of different genetic mod-
iﬁcations that resulted in signiﬁcantly reduced cartilage erosion
(n = 2), worsened damage (n = 1), and no change (n = 1), on
the SCB and osteophytes in OA were examined. Meta-analysis
using partial correlations and general linear models, both within
strains and using pooled data were performed. Cartilage damage
increased signiﬁcantly with time after surgery in all WT strains.
While mean osteophyte size and maturity increased with time in
WT mice, there was no correlation with cartilage damage score.
SCB changes were dependent on background strain, with only
one showing a signiﬁcant change with time and OA progression.
Where cartilage damage was inhibited by the genetic mutation, a
signiﬁcant association was found between chondroprotection and
SCB change in only one of the strains. These studies suggest
independent regulation of bone and cartilage change in this OA
model, and that targeting cartilage matrix degradation will not in-
hibit SCB pathology or osteophyte development in post-traumatic
OA. How this impacts on OA-related pain and disability in these
mice is the subject of ongoing studies.
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DESIGNING AN OA CLINICAL TRIAL
J.-P. Pelletier, J.-P. Raynauld, J. Martel-Pelletier
Osteoarthritis Res. Unit, Notre-Dame Hosp., Univ. of Montreal
Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada
To date clinical studies in osteoarthritis (OA) have focused largely
on the alleviation of signs and symptoms. However, the main
objectives in the management of OA are not only to reduce
symptoms and minimize functional disability, but also to limit
progression of joint structural changes. The last decades have
witnessed several interesting advances in the treatment of OA.
A clearer understanding of the pathophysiology and risk factors
associated with the disease has facilitated the development of
new approaches to treatments aimed at speciﬁcally and effectively
retarding its progression. New classes of molecules that inhibit
one or more OA catabolic processes are under evaluation for their
potential to alter the degenerative process.
The design of OA drug trials aimed at evaluating the relief of
the disease symptoms has been well worked out over the last
few decades with ample expertise having been generated from
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the large number of studies. Also much progress has been made
in establishing reliable “responder criteria”, which has further im-
proved the reporting of results of these trials.
Interest has grown in the discovery of drugs and treatment that
can reduce or stop disease progression. A number of treatments
including symptomatic slow-acting drugs in OA (SYSADOA) from
the naturoceutical ﬁeld have demonstrated the capability of some
to reduce the loss of cartilage in knee and hip OA patients. Thus
far, very little is known about the effect of such treatment on
other joint structural changes that take place during the disease
process. In spite of all the progress made in the symptomatic
treatment of OA, the development of new disease modifying OA
drugs (DMOADs) and/or agents is clearly lagging behind and
major advancements are urgently needed. The development of
DMOADs is facing a number of challenges. The ﬁrst one being the
regulatory environment in which the ﬁeld needs an actualization of
the R&D aspect for DMOAD research programs using for instance
recent scientiﬁc advances.
Indeed the actual tools used for the evaluation of disease symp-
toms in long-term DMOAD clinical trials, as well as joint structural
changes, could beneﬁt from being reassessed in light of the re-
sults from recent trials. The impact of DMOAD treatment on the
function and quality of life of OA patients should include a more
global evaluation, including joint structural assessment. This is of
particular importance as the disease symptoms of one particu-
lar joint (target joint) often do not necessarily correlate with the
severity of structural changes.
The reliability and sensitivity of the technology used for joint struc-
ture to assess the effectiveness of treatment urgently need to be
revisited. For instance, X-rays are still recognized as gold standard
by most regulatory agencies for knee or hip DMOAD clinical trials.
It is now well demonstrated that this technique has several sig-
niﬁcant limitations including weak sensitivity to change. Important
progress has been made in the development of technologies in-
cluding MRI which can assess and quantify joint structural changes
occurring in OA and, more speciﬁcally, in the knee and the hip.
MRI can detect disease progression in a much larger percentage
of knee OA patients compared to X-rays and in a shorter time
frame. Furthermore, it is possible when using MRI to document
the role played by a number of risk factors in the progression of the
disease such as meniscal lesions and subchondral bone marrow
lesions. The ﬁrst multicentre DMOAD clinical study done in knee
OA patients with a follow-up of two years using quantitative MRI
was recently completed with the results supporting the superiority
of MRI over X-rays in DMOAD clinical trials.
An additional challenge for DMOAD trials is the need to better
deﬁne the outcome measures. It has been suggested that total
joint replacement of hip or knee could be a valid outcome measure
for structure modifying trials in OA. Different initiatives are now
in progress to deﬁne alternative endpoints to allow its successful
implementation into DMOAD trials. Notions such as “time to joint
replacement” and “virtual joint replacements” are being explored.
Much work remains to be done in improving the design of DMOAD
clinical trials and selecting DMOA drugs and agents. In particular,
a clariﬁcation of study outcomes is an important milestone that
has yet to be achieved.
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EPIGENETICS AND CARTILAGE DEGENERATION
H.I. Roach
Univ. of Southampton, Southampton, United Kingdom
Purpose: Epigenetic mechanisms determine cell-type speciﬁc
gene expression and mediate interactions between the environ-
ment and the genome. Two major aspects are DNA methylation
and histone modiﬁcations. Genes that are part of the expression
repertoire of a somatic cell type show DNA hypo-methylation, ac-
tivating histone modiﬁcations such as acetylation, and chromatin
has an open structure. This permits binding of speciﬁc inductive
or repressive factors to the relevant promoters and facilitates rapid
changes in transcription of cell-type speciﬁc genes. Genes that
are never expressed by a particular somatic cell are permanently
silenced by DNA methylation, repressive histone modiﬁcations
and chromatin condensation; this prevents access of the rele-
vant transcription factors to the promoters. During cell division,
the DNA methylation pattern is rapidly reproduced by the mainte-
nance DNA methyl transferase (DNMT1). The histone code can
be re-established by interactions of methyl binding domains and
DNMTs with histone methyltransferases and histone deacetylases
so that both the DNA methylation pattern and the histone code
are reproduced during mitosis.
Methods: DNA methylation is generally stable in somatic cells
throughout adult life and epigenetic disruption may activate nor-
mally silent genes or silence normally expressed genes.
Results: This is precisely the situation in osteoarthritic chon-
drocytes, where many non-chondrocytic genes are permanently
activated. For example, articular chondrocytes normally do not
express cartilage-degrading enzymes or IL-1β, and the promoters
of these genes are heavily methylated. However, loss of methyla-
tion at speciﬁc CpG sites has occurred in chondrocytes from OA
patients (Arthritis & Rheum. 52:3110-24), which enables an ‘unsi-
lencing’ and consequent aberrant expression of non-chondrocytic
genes. This de-methylation was also observed in a 23-year old,
who had osteoarthritis as a consequence of Developmental Dys-
plasia of the Hip, suggesting that DNA de-methylation was not just
a consequence of age, but an integral part of the disease process.
The factors that might cause loss of DNA methylation are still
unknown. We have shown that inﬂammatory cytokines have the
capacity to change DNA methylation status, at least in vitro,
although the exact mechanisms can only be speculated upon.
Conclusions: One can envisage the following scenario in os-
teoarthritis: In the acute phase following injury, inﬂammatory cy-
tokines, produced by cells of an inﬂamed synovium, diffuse into the
cartilage and cause loss of DNA methylation resulting in ‘unsilenc-
ing’ of proteases and IL-1β in chondrocytes of the superﬁcial zone.
In the subsequent chronic phase, cytokines produced by chondro-
cytes diffuse to adjacent chondrocytes and repeat the process. In
this phase, there is no further requirement of synovial cytokines
and the process is self-perpetuating, which may explain the in-
evitable progression of cartilage degradation from the superﬁcial to
the deep zone. If the loss of DNA methylation could be prevented,
then presumably the aberrant induction of non-chondrocytic genes
could be prevented and ultimately the progression of OA might be
slowed down or even halted.
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INNATE IMMUNE SYSTEM ACTIVATION IN OA: IS OA A
CHRONIC WOUND?
C.R. Scanzello
Rush Univ. Med. Ctr., Chicago, IL
Once considered a non-inﬂammatory disease of articular cartilage,
osteoarthritis (OA) is now understood to be a complex condition
affecting all joint tissues. Synovial inﬂammation is increasingly
recognized as an important process, however inﬂammation can
be deﬁned in diverse ways: by clinical examination, advanced
imaging techniques, or at the cellular or molecular level by cellular
inﬁltration, soluble mediators, and activated signalling pathways.
Imaging [1] and arthroscopic [2] studies have pointed to the clinical
importance of inﬂammation in OA patients. Evidence emerging at
the cellular and molecular level will be discussed which implicates
activation of the innate immunity.
